Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Status
- RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Rilvegostomig
Related studies linked through entity extraction aliases.
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
- Status
- RECRUITING
- Phase
- PHASE3
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE2
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE3
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
- Status
- RECRUITING
- Phase
- PHASE3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Status
- RECRUITING
- Phase
- PHASE3
Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
- Status
- RECRUITING
- Phase
- PHASE3
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
- Status
- RECRUITING
- Phase
- PHASE3
PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC
- Status
- RECRUITING
- Phase
- EARLY_PHASE1
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Status
- RECRUITING
- Phase
- PHASE3
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE2